Designer monoclonal antibodies as drugs: The state of the art

Expert Review of Clinical Immunology

Volumn 4, Issue 3, 2008, Pages 305-307

  Mohapatra, Shyam ^a   San Juan, Homero ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSIDAD DEL NORTE   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACLIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOMODULATING AGENT; INFLIXIMAB; MESSENGER RNA; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RECPRO; RIBOSOME RNA; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; ZANOLIMUMAB;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN SPECIFICITY; BINDING AFFINITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG LEGISLATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; HYBRIDOMA; IMMUNOGENICITY; MEDICAL TECHNOLOGY; METASTASIS POTENTIAL; MOLECULAR CLONING; NONHUMAN; PHAGE DISPLAY;

EID: 46249088950     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.3.305     Document Type: Editorial

References (11)

1. Carter PJ. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357 (2006).
2. Milstein C. The hybridoma revolution: an offshoot of basic research. Bioessays 21, 966-973 (1999).
3. Carmen S, Jermutus L. Concepts in antibody phage display. Brief Funct. Genomic Proteomic 1, 189-203 (2002).
4. Hoe RMt, Cohen EH, Kent RB et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat. Biotechnol. 23, 344-348 (2005).
5. Siegel RW, Coleman JR, Miller KD, Feldhaus MJ. High efficiency recovery and epitope-specific sorting of an scFv yeast display library. J. Immunol. Methods 286, 141-153 (2004).
6. McGuinness BT, Walter G, FitzGerald K et al. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments. Nat. Biotecbnol. 14, 1149-1154 (1996).
7. Feldhaus MJ, Siegel RW. Yeast display of antibody fragments: a discovery and characterization platform. J. Immunol. Methods 290, 69-80 (2004).
8. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol. 25, 1134-1143 (2007).
9. Lonberg N. Human monoclonal antibodies from transgenic mice. Handb. Exp. Pharmacol. 69-97 (2008).
10. Wu M, Rivkin A, Pham T. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin. Ther. 30, 14-30 (2008).
11. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23, 1105-1116 (2005).